title: Prolonged survival after treatment of diffuse intrinsic pontine glioma with radiation, temozolamide, and bevacizumab:  report of 2 cases.
abstract: BACKGROUND
  Diffuse intrinsic pontine gliomas have poor prognosis.
  
  
  METHODS
  We report on 2 patients with diffuse intrinsic pontine glioma treated with radiation, followed by temozolamide 200 mg/m/d for 5 days every 28 days and bevacizumab 10 mg/kg/dose every 14 days. Both patients have ongoing PFS of 37 and 47 months from diagnosis. A decrease in tumor size by >65% was observed in both the patients. Both patients continue treatment. No steroid requirement since 10 weeks after radiation. Quality of life is excellent and the chemotherapy regimen is well tolerated.
  
  
  CONCLUSIONS
  A clinical trial in an expanded cohort is warranted to determine the toxicity and evaluate response.
authors.affiliation: Aflac Center for Cancer and Blood Disorders Service, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, GA 30322, USA.
authors.forename: Dolly G
authors.initials: DG
authors.lastname: Aguilera
authors.forename: Claire
authors.initials: C
authors.lastname: Mazewski
authors.forename: Laura
authors.initials: L
authors.lastname: Hayes
authors.forename: Cathy
authors.initials: C
authors.lastname: Jordan
authors.forename: Natia
authors.initials: N
authors.lastname: Esiashivilli
authors.forename: Anna
authors.initials: A
authors.lastname: Janns
authors.forename: Tobey J
authors.initials: TJ
authors.lastname: Macdonald
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D020295:Brain Stem Neoplasms / Q000401:mortality* / Q000628:therapy; D059248:Chemoradiotherapy; D002648:Child; D003606:Dacarbazine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D005910:Glioma / Q000401:mortality* / Q000628:therapy; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D011149:Pons; D011379:Prognosis; D015996:Survival Rate; D000077204:Temozolomide
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003606:Dacarbazine; D000077204:Temozolomide